Miranda Jonatan, Arias Noemi, Fernández-Quintela Alfredo, del Puy Portillo María
Grupo Nutrición y Obesidad, Departamento de Farmacia y Ciencias de los Alimentos, Facultad de Farmacia, Universidad del País Vasco, Vitoria, España; CIBERobn, Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, España.
Grupo Nutrición y Obesidad, Departamento de Farmacia y Ciencias de los Alimentos, Facultad de Farmacia, Universidad del País Vasco, Vitoria, España; CIBERobn, Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, España.
Endocrinol Nutr. 2014 Apr;61(4):209-19. doi: 10.1016/j.endonu.2013.04.016. Epub 2013 Sep 10.
Despite its benefits, conjugated linoleic acid (CLA) may cause side effects after long-term administration. Because of this and the controversial efficacy of CLA in humans, alternative biomolecules that may be used as functional ingredients have been studied in recent years. Thus, conjugated linolenic acid (CLNA) has been reported to be a potential anti-obesity molecule which may have additional positive effects related to obesity. According to the results reported in obesity, CLNA needs to be given at higher doses than CLA to be effective. However, because of the few studies conducted so far, it is still difficult to reach clear conclusions about the potential use of these CLNAs in obesity and its related changes (insulin resistance, dyslipidemia, or inflammation).
尽管共轭亚油酸（CLA）有诸多益处，但长期服用后可能会产生副作用。鉴于此以及CLA在人体中的功效存在争议，近年来人们对可作为功能成分使用的替代生物分子进行了研究。因此，共轭亚麻酸（CLNA）已被报道为一种潜在的抗肥胖分子，可能对肥胖症有其他积极作用。根据肥胖症研究报告的结果，CLNA要想发挥作用，所需剂量比CLA更高。然而，由于目前开展的研究较少，关于这些CLNA在肥胖症及其相关变化（胰岛素抵抗、血脂异常或炎症）方面的潜在用途，仍难以得出明确结论。
